CAMBRIDGE, Mass., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal rare diseases, announced that the Boston Globe has named the company one of the Top Places to Work in Boston in 2013.
"Aegerion has experienced significant growth in the past year, and one of our top priorities is to maintain our employee-focused culture," said Marc D. Beer, Chief Executive Officer of Aegerion. "Having Aegerion employees elect the Company as a Top Place to Work is a source of great pride for our organization. This honor is a reflection of our dedicated employees who pursue our mission to treat patients with rare diseases."
Aegerion ranked 20th out of 115 in the small employer category, defined as companies with 50-99 Massachusetts-based employees. Aegerion has approximately 150 total employees globally.
Rankings were based on composite scores calculated on the basis of employee responses. The survey was conducted by WorkPlace Dynamics of Exton, Pa., specialists in employee engagement and retention. Employers were rated based on workplace practices in compensation, leadership, appreciation, career opportunities and management.
The full article including the list of honorees can be found at: www.bostonglobe.com/topplaces.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com.